Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

Core Viewpoint - Edesa Biotech, Inc. is advancing its drug candidate EB06 for treating moderate-to-severe nonsegmental vitiligo and has reported financial results for the three and nine months ended June 30, 2025, indicating a strategic focus on this development program [1][2][3]. Financial Performance - For the three months ended June 30, 2025, total operating expenses were $1.9 million, consistent with the same period in 2024 [5]. - The net loss for the quarter was $1.7 million, or $0.25 per common share, compared to a net loss of $1.7 million, or $0.52 per common share, for the same period in 2024 [6]. - For the nine months ended June 30, 2025, total operating expenses decreased by $0.6 million to $5.4 million compared to $6.0 million for the same period in 2024 [7]. - The net loss for the nine months was $5.0 million, or $0.95 per common share, compared to a net loss of $5.2 million, or $1.64 per common share, for the same period in 2024 [10]. Research and Development Focus - Research and development expenses for the nine months ended June 30, 2025, decreased by $0.4 million to $2.4 million, primarily due to reduced external research expenses related to EB05, offset by increased expenses for EB06 [7]. - The company is channeling operational efforts into regulatory preparation and drug manufacturing for EB06, aiming for rapid progression into clinical testing [4]. Cash Position and Working Capital - As of June 30, 2025, Edesa had cash and cash equivalents of $12.4 million and working capital of $12.1 million [11]. Upcoming Events - Edesa management is scheduled to participate in the Canaccord Genuity 45th Annual Growth Conference on August 12-13, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025 [12].